Evidence based respiratory medicine: 2nd update workshop of the SPLF. Chronic obstructive pulmonary disease;Pneumologie fondée sur les preuves: Actualisations SPLF séminaire n° 2. Bronchopneumopathie chronique obstructive

Revue des Maladies Respiratoires

Volumn 21, Issue 4 I, 2004, Pages 845-848

  Chaouat, A ^a   Roche, N ^b  

^a HÔPITAL DE HAUTEPIERRE   (France)

^b HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; THEOPHYLLINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DYSPNEA; EVIDENCE BASED MEDICINE; HUMAN; PREVALENCE; PROGNOSIS; RISK FACTOR; FRANCE; REVIEW;

FRANCE; HUMANS; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 7044239605     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8425(04)71431-x     Document Type: Conference Paper

References (27)

1. National Heart Lung and Blood Institute, NIH, World Health Organization: Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease. Executive summary. 2000.
2. Société de Pneumologie de Langue Française: Recommandations pour la prise en charge de la bronchopneumopathie chronique obstructive. Rev Mal Respir 2003; 20: 294-329.
3. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P, Owens GR, Scanlon PD, Tashkin DP, Wise RA: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. Jama 1995; 272: 1497-505.
4. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-90.
5. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B: Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-5.
6. Bolliger CT, Zellweger JP, Danielsson T, van B, X, Robidou A, Westin A, Perruchoud AP, Sawe U: Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. BMJ 2000; 321: 329-33.
7. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor WD, Newhouse MT: Bronchodilators in chronic air-flow limitation. Am Rev Respir Dis 1987; 135: 1069-74.
8. O'Donnell DE, Lam M, Webb KA: Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 542-9.
9. Bone R, for The Combivent Inhalation Aerosol Study et al.: Combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994; 105 1411-9.
10. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ: Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209-16.
11. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della CG: Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 778-84.
12. Murciano D, Auclair MH, Pariente R, Aubier M: A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521-5.
13. Decramer M, Lacquet LM, Fagard R, Rogiers P: Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150: 11-6.
14. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA: Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003; 58: 654-8.
15. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-303.
16. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV: Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-53.
17. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-23.
18. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-56.
19. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T: Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2002; 166: 1084-91.
20. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
21. Nannini L, Lasserson T, Poole P: Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003; 4: CD003794.
22. Dal Negro RW, Pomari C, Tognella S, Micheletto C: Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 2003; 16: 241-6.
23. Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rudkin S, Whyte K: Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. Eur Respir J 2002; 20: 306-12.
24. Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF, Ambrosino N: The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20: 529-38.
25. Meecham JD, Paul EA, Jones PW, Wedzicha JA: Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 1995; 152: 538-44.
26. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE: A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-73.
27. National Emphysema Treatment Trial Group: Patients at high risk of death after lung volume reduction surgery. N Engl J Med 2001; On line publication August 2001; 14.